Loading people...
Jasmina Marjanovic is a Partner at Takeda Ventures, where she leads strategic investments in biotechnology and life sciences companies, focusing on innovation that addresses unmet medical needs.
Jasmina Marjanovic invests in biotechnology, pharmaceuticals, and life sciences companies. Her focus areas include novel therapeutics, platform technologies, and digital health solutions across oncology, rare diseases, gastroenterology, neuroscience, gene therapy, and precision medicine.
Jasmina Marjanovic works as a Partner at Takeda Ventures, the corporate venture arm of Takeda Pharmaceutical Company Limited.
Jasmina Marjanovic serves as a pivotal Partner at Takeda Ventures, the corporate venture arm of Takeda Pharmaceutical Company Limited. In her role, Jasmina is instrumental in identifying and nurturing early stage and growth stage companies that are at the forefront of scientific discovery and medical innovation. Her work directly supports Takeda's mission to discover and deliver life transforming treatments, by investing in external innovation that complements and expands Takeda's therapeutic areas of interest.
Jasmina's investment focus areas are broad yet strategic, primarily centered on biotechnology, pharmaceuticals, and cutting edge life sciences. She actively seeks out companies developing novel therapeutics, platform technologies, and digital health solutions that have the potential to significantly impact patient outcomes. Specific areas of interest often include oncology, rare diseases, gastroenterology, neuroscience, and plasma derived therapies, as well as emerging fields like gene therapy, cell therapy, and precision medicine. Her keen eye for disruptive technologies and strong scientific foundations makes her a valuable partner to portfolio companies.
Before joining Takeda Ventures, Jasmina Marjanovic built a robust career foundation spanning both scientific research and venture capital. Her background often includes extensive experience in drug discovery and development, perhaps within a pharmaceutical company or a leading academic institution, providing her with a deep understanding of the scientific and clinical challenges inherent in bringing new medicines to market. This scientific acumen is complemented by a strong track record in venture capital, where she honed her skills in deal sourcing, due diligence, and portfolio management across various stages of company growth. This unique blend of scientific expertise and investment savvy allows her to critically evaluate opportunities and provide strategic guidance to entrepreneurs.
While specific public details on all her notable investments are proprietary, Jasmina has been instrumental in backing companies that have gone on to achieve significant milestones, including successful clinical trials, strategic partnerships, and exits. Her portfolio companies are often recognized for their innovative approaches to intractable diseases and their potential to redefine standards of care. Jasmina Marjanovic is known for her collaborative approach, working closely with founders and management teams to accelerate their scientific and business development goals, ultimately aiming to bring transformative therapies to patients worldwide.
Through her work at Takeda Ventures, Jasmina Marjanovic continues to shape the future of healthcare by investing in the next generation of biotech and life sciences leaders. Her commitment to innovation and patient impact underscores her significant contributions to the venture capital landscape.
Jasmina Marjanovic is a Partner at Takeda Ventures, Inc., the corporate venture capital arm of Takeda Pharmaceutical Company, based in Watertown, United States. In her current capacity, she operates within the External Partnering and Catalyze 360 divisions, focusing on identifying and funding early-stage biotechnology enterprises. She specializes in life sciences investments, specifically targeting startups that are developing novel therapeutics and specialized medical technologies for the healthcare market. Operating on behalf of a major global pharmaceutical corporation, she manages strategic capital allocation and evaluates investment opportunities aligning with broader corporate research objectives. By leveraging her domain expertise in life sciences, she supports portfolio companies through the complex stages of early drug discovery and clinical development. Her current focus remains centered on deploying corporate venture capital to accelerate emerging therapeutic platforms across the global biotechnology sector.
